ArticleNucleic acids research2025
A NanoLock-enabled, Craspase-based strategy for highly sensitive RNA detection.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Craspase Protease Activation Is Sensitive to Oncogenic Single-Nucleotide RNA Mismatches.ACS chemical biology · 2026Article
- Influenza virus research in an era of emerging respiratory threats: host-virus interactions, surveillance technologies, antiviral management and resistance, and vaccine preparedness.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Rapid and sensitive detection of RNA is important in fields such as biomedical research and clinical diagnostics. However, current methods typically involve an amplification process, require substantial time, and are susceptible to aerosol contamination. Herein, we introduce a NanoLock-powered, amplification-free assay based on the type III-E clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated system for rapid, highly sensitive, and specific RNA diagnostics. This innovative platform, designated CRISPR-guided caspase (Craspase)-NanoLock-Csx30 (CNC), harmoniously integrates the precise protease activity of Craspase with the remarkable luminescent sensitivity of NanoLock, creating a novel and streamlined approach for RNA detection. The CNC platform exhibited exceptional sensitivity in detecting severe acute respiratory syndrome coronavirus-2 N gene RNA through the integration of three guide RNAs, achieving a detection limit of 250 fM in just 10 min without amplification. Preliminary studies further revealed the platform's extended diagnostic potential for detecting influenza A virus and human immunodeficiency virus. These findings collectively establish the CNC platform as an appealing tool for infectious disease detection and significantly broaden the scope of CRISPR-based diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.